Boston Scientific Analyst Ratings
IDEXX Laboratories Board Authorizes Increase In Its Ongoing Share Repurchase Program, Authorizing Repurchase Of Up To 5M Additional Shares
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
Stocks With Best Odds of Risk-adjusted Returns Deserve Attention: Goldman Sachs
Key Deals This Week: Shell-Equinor U.K. Combination, Hershey, TotalEnergies, GE HealthCare and More
Wells Fargo's 'Core' List: GOOGL, DIS, HD, WMT, and More!
Peering Into Abbott Laboratories's Recent Short Interest
11 Compounder Opportunities According to Goldman: AMD, BDX, INFA
(ISRG) - Analyzing Intuitive Surgical's Short Interest
Intuitive Surgical Analyst Ratings
Oppenheimer Asset Management Places Buy Ratings on AVGO and BLDR and a Sell Call on EW
GE Healthcare Unveiled 3 New Advanced Deep Learning Image Processing And Reconstruction Solutions As A Part Of Its Effortless Recon DL Portfolio At The Radiological Society Of North America 2024 Annual Meeting
Edwards Lifesciences Analyst Ratings
Edwards Lifesciences Outlines Vision For Growth At Investor Conference
Edwards Lifesciences Shares Are Trading Higher After Company Provided an Updated FY25 Guidance.
Edwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%
(BSX) - Analyzing Boston Scientific's Short Interest
Price Over Earnings Overview: Medtronic
Stocks With Improving and Deteriorating 'TechniGrade' by Piper Sandler
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks